Clinical trial
Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder
NCT00299611 · Duke University, Other · Terminated
Key facts
| NCT number | NCT00299611 |
|---|---|
| Title | Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder |
| Official title | A Double-Blind Augmentation Study of LEvetiracetam in Obsessive Compulsive Disorder |
| Lead sponsor | Duke University, Other |
| Collaborators | UCB Pharma Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Obsessive-Compulsive Disorder |
| Intervention type | Drug |
| Interventions | Sertraline, Levetiracetam, Placebo |
| Enrollment | 12 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Apr 1, 2008 |
| First posted | Mar 7, 2006 |
| Last update posted | Apr 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: